EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adults With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab for Over 1 Year Achieve Optimal Treatment Response by Patient-Reported Outcomes

Eric L. Simpson, Michael J. Cork, Yoko Kataoka, Amy H. Praestgaard, Zhixiao Wang, Ana B. Rossi

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s831

DOI: 10.25251/22mprb06 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Eric L. Simpson und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the proportion of adults with moderate-to-severe atopic dermatitis treated with dupilumab monotherapy who achieved a continued minimal disease activity over time (as measured by the achievement of individual patient-reported outcome targets).

Introduction

Achieving and maintaining minimal symptoms and disease impact are important goals for patients with atopic dermatitis (AD). We assessed the proportion of adults with moderate-to-severe AD receiving dupilumab monotherapy who achieved minimal disease activity over time as measured by patient-reported outcome (PRO) instruments.

Methods

Adults with moderate-to-severe AD achieving Investigator’s Global Assessment (IGA)=0/1 and/or Eczema Area and Severity Index-75 (EASI-75) after 16 weeks of dupilumab 300 mg every two weeks (q2w) monotherapy in LIBERTY AD SOLO 1/2 (n=199; NCT02277743, NCT02277769) were re-randomized for 36 additional weeks to placebo or dupilumab 300 mg q2w, every 4 weeks (q4w), or every 8 weeks (q8w) in SOLO-CONTINUE (NCT02395133). The proportion of patients achieving optimal results in each PRO (Dermatology Life Quality Index [DLQI]=0–1, Patient Global Assessment of Disease Status [PGADS]=very good/excellent, Patient Global Assessment of Treatment Effect [PGATE]=very good/excellent, total Patient-Oriented Eczema Measure [POEM]=0–2) at the end of SOLO 1/2 and the end of SOLO-CONTINUE are reported. Patients who discontinued or received systemic rescue were set to non-responders; missing values were addressed through multiple imputation regardless of rescue treatment.

Results

Among re-randomized patients (responders) in SOLO-CONTINUE, proportions achieving target endpoints at both Week 16 and Week 52 were higher with active dupilumab dosing than placebo across measures. DLQI: dupilumab q2w 66%, q4w 72%, q8w 61%, placebo 7%. PGADS: dupilumab q2w 75%, q4w 68%, q8w 50%, placebo 22%. PGATE: dupilumab q2w 80%, q4w 79%, q8w 49%, placebo 26%. POEM: dupilumab q2w 73%, q4w 75%, q8w 38%, placebo 11%. Safety was consistent with the known safety profile.

Conclusions

Most responder patients at Week 16 achieved and maintained minimal disease activity according to PROs at Week 52 with q2w and q4w dupilumab monotherapy maintenance dosing. Acknowledgments and Funding Sources: Data included in this abstract were originally presented at the 84th Annual Meeting of the American Academy of Dermatology (AAD); Denver, CO, USA; March 27–31, 2026. Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifiers: NCT02277743, NCT02277769, NCT02395133. Medical writing/editorial assistance was provided by Jacqueline Moy, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.

Zitieren

APA

Simpson, E. L., Cork, M. J., Kataoka, Y., Praestgaard, A. H., Wang, Z., & Rossi, A. B. (2026). Adults With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab for Over 1 Year Achieve Optimal Treatment Response by Patient-Reported Outcomes. SKIN The Journal of Cutaneous Medicine, 10(6), s831. https://doi.org/10.25251/22mprb06

Vancouver

Simpson EL, Cork MJ, Kataoka Y, Praestgaard AH, Wang Z, Rossi AB. Adults With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab for Over 1 Year Achieve Optimal Treatment Response by Patient-Reported Outcomes. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s831. doi:10.25251/22mprb06

BibTeX
@article{Simpson2026,
  author = {Simpson, Eric L. and Cork, Michael J. and Kataoka, Yoko and Praestgaard, Amy H. and Wang, Zhixiao and Rossi, Ana B.},
  title = {Adults With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab for Over 1 Year Achieve Optimal Treatment Response by Patient-Reported Outcomes},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s831},
  doi = {10.25251/22mprb06}
}
Kostenlos starten →